J. Y. Douillard, P. M. Hoff, J. R. Skillings, et al., “Multicenter Phase III Study of Uracil/Tegafur and Oral Leucovorin versus Fluorouracil and Leucovorin in Patients with Previously Untreated Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 20, No. 17, 2002, pp. 3605-3616. doi:10.1200/JCO.2002.04.123

has been cited by the following article:

• TITLE: Feasibility and Efficacy Study of Biweekly Irinotecan Combined with Oral Tegafur/Uracil in Advanced Colorectal Cancer

  AUTHORS: Masataka Ikeda, Mitsugu Sekimoto, Ichiro Takemasa, Tsunekazu Mizushima, Hirofumi Yamamoto, Hideshi Ishii, Yuichiro Doki, Masaki Mori

  KEYWORDS: Colorectal Neoplasms; Pharmacokinetics; Drug Therapy; Fluorouracil; Tegafur/Uracil; UFT

  JOURNAL NAME: Journal of Cancer Therapy, Vol.4 No.6B, July 5, 2013

  ABSTRACT: Background: We evaluated the feasibility and efficacy of irinotecan (CPT-11) plus tegafur/uracil (UFT) combination chemotherapy in patients with advanced colorectal cancer. Patients and Methods: PK parameters were concurrently measured to confirm the presence of drug interactions in this treatment schedule. CPT-11 was administered intravenously at the dose of 150 mg/m2 on days 1, 15. UFT was administered at the dose of 375 mg/m2/day (B.I.D.) on days 3 - 7, 10 - 14, 17 - 21, 24 - 28 repeated every 5 weeks. Results: 31 patients were enrolled. PK parameters for CPT-11, FT, 5-FU and uracil are available from 5 patients. The overall response rate was 16.1%. The median time to treatment discontinuation was 3.9 months. There was no significant difference in PK parameters of CPT-11 between day 1 and day 15 and of UFT between day 3 and day 10. Conclusion: CPT-11 plus UFT combination chemotherapy exhibited a tolerable toxicity profile with acceptable efficacy. Pharmacokinetic analysis showed that there were no drug interactions in this treatment schedule.